Diagnostic Nano Technology to use Instant Detect Technology to detect H1N1 virus

Diagnostic Nano Technology Corporation (DNA), a subsidiary of Avisio, Inc. (PINKSHEETS: AVIC), announced today that with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that cause Dengue Fever, it plans to begin testing the technology on the detection of the H1N1 virus.

"Ongoing testing of this type is a necessary component in the process of selecting DNA's initial human application development projects," said Amro Albanna, CEO of DNA and Avisio, Inc. "We are cautiously optimistic about the market opportunity that exists for DNA's Instant Detect product, especially with regard to potential human applications. We realize that we are early in the process and still have a number of milestones to reach, including but not limited to further proof of concept, the ability to produce product at scale, third-party validation and regulatory approvals, before we can begin to market a product," continued Albanna.